The Protein Production, Characterization and Molecular Interaction (PPCMI) core provides cloning, expression and purification services of functional proteins at a scale that meets the quantity and purity benchmarks for structural, biophysical, biochemical, and therapeutics studies; it also characterizes macromolecular biophysics and interaction energetics using a wide variety of state-of-the-art instrumentation and techniques that can analyze association and kinetic binding constants by surface plasmon resonance, enthalpies and entropies of binding by isothermal titration calorimetry, as well as determination of stoichiometry, stability, and homogeneity by both techniques.

The IBT Flow Cytometry and Cell Sorting Facility (FCCSF) provides a wide array of cutting-edge flow cytometry and cell sorting services, along with the necessary scientific expertise to integrate this technology into your research projects.

In 2020, The High Throughput Flow Cytometry Program (HtFCP) received funding from CPRIT, in conjunction with the existing Combinatorial Drug Discovery Program (CDDP), both integral components of the Gulf Coast Consortia network. This partnership provides academic and commercial users with unprecedented access to the only High Throughput Flow Cytometry automated platform in Texas Medical Center. The HtFCP and High Throughput Research Screening Core CDDP now call the state-of-the-art TMC3 Helix Park Collaborative Building, their home, located at 7255 Helix Park, Houston, TX 77030.

The Microphysiological Leads Optimization and Toxicity Screening facility (MLOTS) supports lead optimization programs and has established a roster of medium-throughput microphysiologic screening platforms including tissue- and tumor-on-a-chip platforms, organoid, and spheroid culture systems that will be used to evaluate the efficacy and toxicity of new lead compounds and drug combinations.

The pharmaceutical industry has recognized the importance of implementing a “fail early” screening strategy early in the drug development process by adopting advanced physiological screening platforms and predictive in vitro toxicology testing. MLOTS supports a "fail early" approach as a lead optimization strategy by providing the resources to identify. toxic liabilities in lead series molecules before entering pre-clinical or clinical testing. MLOTS can evaluate NME for cardiovascular, neuro, or liver toxicity relative to reference standards using in vitro screening platforms.

The Combinatorial Drug Discovery Program (CDDP) resides in the Texas A&M Health Science Center’s Institute of Biosciences and Technology, Houston, TX. This core provides industry standard high throughput screening and automated microscopy capabilities to scientists performing drug discovery research. The core provides many benefits, such as access to an automated infrastructure that is capable of supporting both both phenotypic and biochemical targets. The CDDP provides ready access to collections of current FDA-approved drugs and clinical candidates exhibiting the ‘drug-like’ qualities of acceptable solubility, desirable ADME/toxicology properties and adequate bioavailability. These properties are important for rapid advancement of new agents into successful preclinical and clinical trials by discovering new therapeutic vulnerabilities alone or in combinations. The CDDP also has collections of mechanistically annotated informer sets that are pathway specific modulators for studying mechanism of action or target identification. The core also has collections of natural products and diverse sets of small molecules that can be interrogated for new target discovery. The greatest benefit of the core; however, is its fulltime professional staff. The screening team is composed of highly experienced biologists, biochemists, pharmacologists and data scientists with both pharmaceutical industry and academic experience. Each project is individually evaluated and a team of scientists from the CDDP is created to fit the specific needs of the project from assay design and development through primary, secondary and orthogonal screening. The team is committed to providing an integrated and highly collaborative program with every investigator.

The primary purpose of the IMIL is to support research progress and grant development by encouraging researchers to explore advanced imaging modalities and to incorporate them into their existing research programs.

The IMIL provides technical expertise and cutting-edge microscope systems to support the research of faculty and staff of Texas A&M University Health Science Center, Texas A&M University, and all other campuses. The IMIL includes six microscopy rooms, supporting facilities, and an image processing station.

Technical staff is available to train and assist with design, implementation, and analysis of experiments as well as assist in troubleshooting.